Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling

Sastry, Konduru S.; Chouchane, Aouatef Ismail; Wang, Ena; Kulik, George; Marincola, Francesco M.; Chouchane, Lotfi

doi:10.1038/cddis.2017.226

Cited by 22 publications

(19 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table S8). A recent study comprehensively investigated the cytoprotective effects of the small neuropeptide VIP and its receptor (VIPR1) in cancer stem cells and identified an antiapoptotic function of the VIP receptor in these cancer cells 74 .…”

Section: Resultsmentioning

confidence: 99%

“…Effectors of the cell cycle are differentially spliced during a 24 h period in our data sets. In particular, VIPR1 , which is involved in the antiapoptotic pathway in cancer cells and acts as proliferation regulator 74 . These results highlight the significance of a failure in the temporal control of alternative splicing which influences major cellular pathways with possible subsequent effects in cancer onset or progression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A bioinformatic analysis identifies circadian expression of splicing factors and time-dependent alternative splicing events in the HD-MY-Z cell line

Genov

Basti

Abreu

et al. 2019

Sci Rep

View full text Add to dashboard Cite

The circadian clock regulates key cellular processes and its dysregulation is associated to several pathologies including cancer. Although the transcriptional regulation of gene expression by the clock machinery is well described, the role of the clock in the regulation of post-transcriptional processes, including splicing, remains poorly understood. In the present work, we investigated the putative interplay between the circadian clock and splicing in a cancer context. For this, we applied a computational pipeline to identify oscillating genes and alternatively spliced transcripts in time-course high-throughput data sets from normal cells and tissues, and cancer cell lines. We investigated the temporal phenotype of clock-controlled genes and splicing factors, and evaluated their impact in alternative splice patterns in the Hodgkin Lymphoma cell line HD-MY-Z. Our data points to a connection between clock-controlled genes and splicing factors, which correlates with temporal alternative splicing in several genes in the HD-MY-Z cell line. These include the genes DPYD , SS18 , VIPR1 and IRF4 , involved in metabolism, cell cycle, apoptosis and proliferation. Our results highlight a role for the clock as a temporal regulator of alternative splicing, which may impact malignancy in this cellular model.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A bioinformatic analysis identifies circadian expression of splicing factors and time-dependent alternative splicing events in the HD-MY-Z cell line

Genov

Basti

Abreu

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…During treatment with drugs, especially in cancer, safety of the normal cells is of a prime concern (Sastry et al, ). Moreover, normal cells under excessive stress should be adequately protected.…”

Section: Neuropharmacological Effects Of β‐Caryophyllenementioning

confidence: 99%

A systematic review on the neuroprotective perspectives of beta‐caryophyllene

Machado

Islam

Ali

et al. 2018

Phytotherapy Research

View full text Add to dashboard Cite

Beta (β)-caryophyllene (BCAR) is a major sesquiterpene of various plant essential oils reported for several important pharmacological activities, including antioxidant, anti-inflammatory, anticancer, cardioprotective, hepatoprotective, gastroprotective, nephroprotective, antimicrobial, and immune-modulatory activity. Recent studies suggest that it also possesses neuroprotective effect. This study reviews published reports pertaining to the neuropharmacological activities of BCAR. Databases such as PubMed, Scopus, MedLine Plus, and Google Scholar with keywords "beta (β)-caryophyllene" and other neurological keywords were searched. Data were extracted by referring to articles with information about the dose or concentration/route of administration, test system, results and discussion, and proposed mechanism of action. A total of 545 research articles were recorded, and 41 experimental studies were included in this review, after application of exclusion criterion. Search results suggest that BCAR exhibits a protective role in a number of nervous system-related disorders including pain, anxiety, spasm, convulsion, depression, alcoholism, and Alzheimer's disease.Additionally, BCAR has local anesthetic-like activity, which could protect the nervous system from oxidative stress and inflammation and can act as an immunomodulatory agent. Most neurological activities of this natural product have been linked with the cannabinoid receptors (CBRs), especially the CB2R. This review suggests a possible application of BCAR as a neuroprotective agent.

show abstract

“…Similarly to NE, VIP is secreted by autonomic nerves in the prostate gland and also can be produced by prostate cancer cells [75,76,77]. In the same way as ADRB2, VIP receptors VIPR1 and VIPR2 are expressed in prostate cancer and engage PKA/pS75BAD mechanism to inhibit apoptosis in prostate cancer cells [78,79]. Sustained phosphorylation of PKA substrates after propranolol therapy would be an indication for activation of adenylyl cyclase and downstream signaling by ADRB2-independent mechanisms (Figure 2A,B).…”

Section: Identifying Prostate Tumors Unresponsive To Propranololmentioning

confidence: 99%

ADRB2-Targeting Therapies for Prostate Cancer

Kulik

2019

Cancers

Self Cite

View full text Add to dashboard Cite

There is accumulating evidence that β-2 adrenergic receptor (ADRB2) signaling contributes to the progression and therapy resistance of prostate cancer, whereas availability of clinically tested β-blocker propranolol makes this pathway especially attractive as potential therapeutic target. Yet even in tumors with active ADRB2 signaling propranolol may be ineffective. Inhibition of apoptosis is one of the major mechanisms by which activation of ADRB2 contributes to prostate cancer pathophysiology. The signaling network that controls apoptosis in prostate tumors is highly redundant, with several signaling pathways targeting a few critical apoptosis regulatory molecules. Therefore, a comprehensive analysis of ADRB2 signaling in the context of other signaling mechanisms is necessary to identify patients who will benefit from propranolol therapy. This review discusses how information on the antiapoptotic mechanisms activated by ADRB2 can guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer. To select patients for clinical trials of propranolol three classes of biomarkers are proposed. First, biomarkers of ADRB2/cAMP-dependent protein kinase (PKA) pathway activation; second, biomarkers that inform about activation of other signaling pathways unrelated to ADRB2; third, apoptosis regulatory molecules controlled by ADRB2 signaling and other survival signaling pathways.

show abstract

Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling

Cited by 22 publications

References 57 publications

A bioinformatic analysis identifies circadian expression of splicing factors and time-dependent alternative splicing events in the HD-MY-Z cell line

A bioinformatic analysis identifies circadian expression of splicing factors and time-dependent alternative splicing events in the HD-MY-Z cell line

A systematic review on the neuroprotective perspectives of beta‐caryophyllene

ADRB2-Targeting Therapies for Prostate Cancer

Contact Info

Product

Resources

About